Amneal Pharmaceuticals (AMRX) is reaching new 5-year highs, up 69% over the past year, with a 100% “Buy” opinion on Barchart. Analysts are positive, with price targets reaching $15. The company is valued at $3.98 billion, focusing on generic, brand, and biosimilar products in North America, Asia, and Europe. Technical momentum is strong, with a 27.56% gain since the Trend Seeker signaled a new “Buy” in October. AMRX hit a 5-year high of $13.37 on Jan. 7, with a Weighted Alpha of +83.10 and a 50-day moving average of $12. Revenue and earnings are expected to grow, with Wall Street analysts giving the stock favorable ratings.

Read more at Yahoo Finance: Can This Healthcare Stock Keep Going After a Nearly 70% Surge?